Retatrutide

Retatrutide is a synthetic peptide engineered as a triple agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors. This unique triagonist structure positions it as a valuable tool for researchers investigating complex metabolic pathways and endocrine functions in controlled laboratory environments. Scientists utilize Retatrutide in preclinical models to explore its effects on energy balance, glucose metabolism, and lipid regulation, providing insights into the synergistic roles of GLP-1, GIP, and GCG receptors. Its properties enable comparative studies with single- and dual-receptor agonists, advancing the understanding of metabolic regulation mechanisms. Each batch is third-party verified for >99% purity, ensuring precision and reliability in experimental outcomes.

All references to metabolic effects, including those related to energy balance or lipid regulation, reflect observations from controlled laboratory research only. This product is intended solely for research purposes and is not for human or animal consumption, nor is it approved for diagnostic, therapeutic, or clinical applications. Restricted to use by qualified research professionals